The Technical AnalystExchange: STO Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Moberg Pharma AB (publ) Price, Forecast, Insider, Ratings, Fundamentals & Signals
-9.52% SEK24.70
America/New_York / 17 mai 2024 @ 11:29
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 690.65 mill |
| EPS: | -1.330 |
| P/E: | -18.57 |
| Earnings Date: | Aug 13, 2024 |
| SharesOutstanding: | 27.96 mill |
| Avg Daily Volume: | 0.645 mill |
| RATING 2024-05-17 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | n/a | n/a | ||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -18.57 | sector: PE 19.76 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.77x |
| Company: PE -18.57 | industry: PE 24.11 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
SEK3.52 (-85.76%) SEK-21.18 |
| Date: 2024-05-18 |
| Expected Trading Range (DAY) |
|---|
|
SEK 21.17 - 28.23 ( +/- 14.29%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | SEK24.70 (-9.52% ) |
| Volume | 0.748 mill |
| Avg. Vol. | 0.645 mill |
| % of Avg. Vol | 115.95 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MOB.ST
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
MOB.ST
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products in Europe, the United States, and internationally. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is headquartered in Bromma, Sweden.